| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0058 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | R428 | CTRPv2 | pan-cancer | AAC | 0.0069 | 0.9 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.0077 | 0.9 |
| mRNA | QL-XII-47 | GDSC1000 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.0082 | 0.9 |
| mRNA | etomoxir | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |
| mRNA | BRD-K75293299 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.9 |